van der Burg, Sjoerd H.

Immunotherapy of established (pre)malignant disease by synthetic long peptide vaccines

Melief, C. J. M., & van der Burg, S. H. (2008) · Nature Reviews Cancer

Immunotherapy and Immune ResponsesT-cell and B-cell Immunology

Cited by 594

Chemotherapy Alters Monocyte Differentiation to Favor Generation of Cancer-Supporting M2 Macrophages in the Tumor Microenvironment

Dijkgraaf, E. M., Heusinkveld, M., Tummers, B., Vogelpoel, L. T. C., Goedemans, R., Jha, V., Nortier, J. W. R., Welters, M. J. P., Kroep, J. R., & van der Burg, S. H. (2013) · Cancer Research

Immune cells in cancerCancer, Stress, Anesthesia, and Immune Response

Cited by 346

PD-L1 checkpoint blockade promotes regulatory T cell activity that underlies therapy resistance

van Gulijk, M., van Krimpen, A., Schetters, S., Eterman, M., van Elsas, M., Mankor, J., Klaase, L., de Bruijn, M., van Nimwegen, M., van Tienhoven, T., et al. (2023) · Science Immunology

Cancer Immunotherapy and BiomarkersT-cell and B-cell Immunology

Cited by 110

Tbet-positive regulatory T cells accumulate in oropharyngeal cancers with ongoing tumor-specific type 1 T cell responses

Santegoets, S. J., Duurland, C. L., Jordanova, E. S., van Ham, J. J., Ehsan, I., van Egmond, S. L., Welters, M. J. P., & van der Burg, S. H. (2019) · Journal for ImmunoTherapy of Cancer

T-cell and B-cell ImmunologyCancer Immunotherapy and Biomarkers

Cited by 48

Simplified Monopalmitoyl Toll‐like Receptor 2 Ligand Mini‐UPam for Self‐Adjuvanting Neoantigen‐Based Synthetic Cancer Vaccines

van den Ende, T. C., Heuts, J. M. M., Gential, G. P. P., Visser, M., van de Graaff, M. J., Ho, N. I., Jiskoot, W., Valentijn, A. R. P. M., Meeuwenoord, N. J., Overkleeft, H. S., et al. (2021) · ChemBioChem

Immunotherapy and Immune ResponsesChemical Synthesis and Analysis

Cited by 9